Featured Research

from universities, journals, and other organizations

Anti-HBe May Play A Role In The Progression Of The Disease Of Hepatitis B

Date:
April 30, 2008
Source:
World Journal of Gastroenterology
Summary:
Researchers have determined that HBV genotype D is the dominant genotype in different clinical forms of either acute or chronic hepatitis. It has been determined that there is a significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals. These results suggest that anti-HBe may play a role in the progression of the disease.

A team led by Dr. A Behzad-Behbahani from Shiraz University of Medical Sciences has determined that HBV genotype D is the dominant genotype in different clinical forms of either acute or chronic hepatitis. It has been determined that there is a significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals. These results suggest that anti-HBe may play a role in the progression of the disease.

Genotype D is found to be the only detected type in different clinical forms of HBV infections, including cirrhosis, among residents of southwestern Iran. A significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals was also determined.

The heterogeneity in the global distribution of HBV genotypes may account for differences in the clinical outcomes of HBV infections and in the responses to antiviral treatment. The clinical and serological statuses of the patients infected with a specific genotype of HBV in this geographic region (southwestern Iran) need to be further investigated.

Serum samples were collected from HBsAg-positive subjects attending the Gastroenterology and Hepatology Clinic at the Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, in southwestern Iran. The definition and diagnostic criteria for clinical terms were adopted from the American Association for the Study of Liver Disease (AASLD) practice guidelines. All sera were then investigated to determine HBV DNA and serological markers. For all the positive quantitative PCR samples, biochemical and histopathological assays and genotyping were also performed. Quantitative real-time PCR assays were carried out using SYBER-Green signal detection. Abdominal ultrasounds were also performed to determine if there were features of cirrhosis. Liver biopsies were performed based on clinical indications.

Genotype D was the only type detected in different clinical forms of acute and chronic infections. There was an increased prevalence of HBeAg-negative status among HBV-infected patients with chronic hepatitis. Cirrhosis was diagnosed among patients with chronic hepatitis. A significant association between the presence of anti-HBe antibody and the increase in ALT levels among either HBeAg-negative or HBeAg-positive individuals was demonstrated. No significant differences were observed between the clinical outcomes of HBeAg-positive and ¨Cnegative patients.

In the view of the authors, this report shows the prevalence of this specific genotype of HBV and its clinical relevance in a part of the Middle East. This isolated genotype is associated with active disease, cirrhosis and hepatocellular carcinoma. A significant number of patients infected with genotype D were HBeAg-negative. Another interesting finding was that a large number of patients with positive anti-HBe had elevated ALT levels.

Using a prospective cohort study in a group of patients infected with HBV genotype D would be helpful to assess the clinical outcomes of different management strategies for the patients. An in vitro study needs to be established in order to clarify the molecular biology of different HBV genotypes.

Further research should explain the mechanism of pathogenesis of different HBV genotypes in specific geographical regions.

Reference: Mojiri A, Behzad-Behbahani A, Saberifirozi M, Ardabili M, Beheshti M, Rahsaz M, Banihashemi M, Azarpira N, Geramizadeh B, Khadang B, Moaddeb A, Ghaedi M, Heidari T, Torab A, Salah AR, Amirzadeh S, Jowkar Z, Mehrabani D, Amini-Bavil-Olyaee S, Dehyadegari MA. Hepatitis B virus genotypes in southwest Iran: Molecular, serological and clinical outcomes. World J Gastroenterol 2008; 14(10): 1510-1513

http://www.wjgnet.com/1007-9327/14/1510.asp


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Cite This Page:

World Journal of Gastroenterology. "Anti-HBe May Play A Role In The Progression Of The Disease Of Hepatitis B." ScienceDaily. ScienceDaily, 30 April 2008. <www.sciencedaily.com/releases/2008/04/080430091755.htm>.
World Journal of Gastroenterology. (2008, April 30). Anti-HBe May Play A Role In The Progression Of The Disease Of Hepatitis B. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/04/080430091755.htm
World Journal of Gastroenterology. "Anti-HBe May Play A Role In The Progression Of The Disease Of Hepatitis B." ScienceDaily. www.sciencedaily.com/releases/2008/04/080430091755.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins